Skip to content

Diabetic Autonomic Neuropathy and Left Ventricular Function

Long - Term Effect of Quinapril or Losartan or Their Combination on Diabetic Autonomic Neuropathy and Left Ventricular Function Over a Period of 4 Years. A Radionuclide Ventriculography Study.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05713396
Acronym
DANEL
Enrollment
59
Registered
2023-02-06
Start date
2017-01-01
Completion date
2022-06-01
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

Purpose: To investigate the effect of Quinapril (Q) or Losartan (L) or their combination on definite Diabetic Autonomic Neuropathy (DAN) and left ventricular systolic and diastolic function (LVF) over a period of 4 years. Patients-methods: Fifty-nine patients with definite DAN \[2 or more of the 4 Cardiovascular Reflex Tests (CRTs) were abnormal\] were studied for 4 years. Patients were randomly allocated in 3 groups receiving A, 20 mg Q, B, 100 mg L and C, 20 mg Q +100 mg L respectively. CRTs analyzed with Mean Circular Resultant (MCR), Valsalva index, 30:15 ratio and postural hypotension. LV function was investigated with radionuclide ventriculography (RNV) at rest. Ejection fraction was used to assess LV systolic function, while peak filling rate, first third filling fraction, and atrial contribution to ventricular filling were used to investigate LV diastolic function. CRTs and RNV were performed at baseline and after 4 years.

Interventions

Per os

DRUGLosartan

Per os

DRUGQuinapril + Losartan

Per os

Sponsors

AHEPA University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. \>18 years old 2. Diabetes mellitus 3. Diabetic autonomic neuropathy

Exclusion criteria

1. Coronary artery disease 2. Arterial hypertension 3. Heart failure with reduced ejection fraction LVEF\<40% 4. Any contraindication to undergo radionuclide ventriculography

Design outcomes

Primary

MeasureTime frameDescription
MCR4 yearsMean Circular Resultant
AV4 yearsAtrial contribution to ventricular filling

Secondary

MeasureTime frameDescription
Valsalva Index4 yearsValsalva Maneuver
30:15 Index4 yearsVariation of R-R interval during postural change
Postural hypotension4 yearsVariation of systolic blood pressure during postural change (standing)
EF4 yearsLeft ventricular ejection fraction
E/I Index4 yearsExpiration/Inspiration Index
PFR4 yearsPeak filling rate Peak filling rate
1/3 FF4 yearsFilling fraction during the first third of the diastole
TPF/FT4 yearsTime to peak filling time/filling time
PER4 yearsPeak emptying rate
SD4 yearsStandard Deviation

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026